

Puma Biotechnology

Earnings Call

Commercial Update




May 9, 2018

nerlynx™
(neratinib) tablets

Forward-Looking Safe Harbor Statement


This presentation contains forward-looking statements, including statements regarding the benefits of NERLYNX® (neratinib) and neratinib, the commercialization of NERLYNX, the potential indications of our drug candidates and the development of our drug candidates, including, but not limited to, the anticipated timing for the commencement and completion of various clinical trials and announcement of data relative to these trials. All statements other than historical facts are forward-looking statements and are based on our current expectations, forecasts and assumptions. Forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These risk and uncertainties are identified in our Annual Report on Form 10-K for the year ended December 31, 2017, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 and any subsequent documents we file with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.

Puma's Pharmacy and Distributor Network




Net Product Sales grew 79% from Q4 to Q1


NERLYNX® Net Sales in \$ M



Net Sales since FDA approval is approximately \$76.3 M




Specialty Pharmacy Enrollments – Through April 30, 2018




- *Specialty Pharmacies account for approximately 88% of total business*

New Patient and Cumulative RX's in Specialty Pharmacies



- Enrollment numbers reported for historical months may be slightly different from previous statements due to SP data updates


NERLYNX[®] Dispenses in the Specialty Pharmacy (SP) Channel



NRx: New Rx Dispensed


TRx: Total Rx Dispensed

Time to First Fill (or shipment) by Specialty Pharmacy




72% of patients receive their first shipment within 15 days of an SP in our network receiving their RX

New and Total NERLYNX® Prescribers in SP Channel



** Prescriber numbers reported for historical months may be slightly different from previous statements due to SP data restatements*

Increasing reach to more targeted prescribers



** Call numbers reported for historical months may be slightly different from previous statements due to Veeva data updates*

Puma Biotechnology

Earnings Call

Commercial Update



May 9, 2018

nerlynx™
(neratinib) tablets